TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8186114
Drug: Calcipotriol solution
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol solution (50 micrograms/ml), applied twice daily for 4 weeks
Study: 8186114
Drug: Placebo (vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle solution), applied twice daily for 4 weeks
Study: 8186114
Drug: Calcipotriol solution
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol solution
Study: 8186114
Drug: Calcipotriol solution
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol solution and Placebo
Study: 25291974
Drug: sifuvirtide 10
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sifuvirtide 10 mg q.d. for 28 days
Study: 25291974
Drug: sifuvirtide 20
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sifuvirtide 20 mg q.d. for 28 days
Study: 25291974
Drug: sifuvirtide 20
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sifuvirtide 20 mg q.d. in combination with HAART for 168 days
Study: 25291974
Drug: sifuvirtide (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: sifuvirtide (both doses)
Study: 21902704
Drug: Novafen (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novafen (325 mg paracetamol, 200 mg ibuprofen, 40 mg caffeine anhydrous)
Study: 18814935
Drug: Diphenhydramine 25
Normalized name: DIPHENHYDRAMINE 25MG CHEW TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 25 mg with metoclopramide 10 mg
Study: 18814935
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with metoclopramide 10 mg
Study: 18814935
Drug: Diphenhydramine 25
Normalized name: DIPHENHYDRAMINE 25MG CHEW TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 25 mg with metoclopramide 20 mg
Study: 18814935
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with metoclopramide 20 mg
Study: 17437152
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (50 mg/kg in 100 ml of saline, followed by 8 mg/kg/h infusion)
Study: 17437152
Drug: Saline (equal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (equal volume before induction and 8 mg/kg/h infusion)
Study: 9777792
Drug: Tazarotene plus
Normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene plus placebo cream
Study: 900433
Drug: Propanidid (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propanidid (7 mg/kg)
Study: 900433
Drug: Etomidate with
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etomidate with faster injection rate (15 seconds)
Study: 27837201
Drug: 0.1% sirolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% sirolimus gel (adults)
Study: 27837201
Drug: 0.05% sirolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% sirolimus gel (adults)
Study: 25754396
Drug: Ertugliflozin 1
Normalized name: ertugliflozin 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin 1 mg
Study: 25754396
Drug: Ertugliflozin 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin 25 mg
Study: 17724727
Drug: apical‐rectal blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: apical‐rectal blockade
Study: 15121563
Drug: Desogestrel pills
Normalized name: desogestrel Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desogestrel pills
Study: 913230
Drug: Butaclamol (BT)
Normalized name: BTS
DrugBank: Pyruvic acid (DB00119)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butaclamol (BT) 10 mg
Study: 913230
Drug: Butaclamol (BT)
Normalized name: BTS
DrugBank: Pyruvic acid (DB00119)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butaclamol (BT) 20 mg
Study: 913230
Drug: Butaclamol (BT)
Normalized name: BTS
DrugBank: Pyruvic acid (DB00119)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butaclamol (BT) 40 mg
Study: 30734717
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid at a daily dose of 500 mg
Study: 30734717
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid at a daily dose of 750 mg
Study: 30734717
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid at a daily dose of 1,000 mg
Study: 30734717
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid at a daily dose of 1,500 mg
Study: 24921623
Drug: Spinach supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinach supplementation (1 g/kg body weight daily for 14 days)
Study: 6662170
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg of long acting (L.A.) propranolol
Study: 6662170
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of sustained action (S.A.) metoprolol
Study: 28240186
Drug: Tender coconut
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tender coconut water (TCW) 300 ml twice daily for 14 days
Study: 28240186
Drug: Water 300
Normalized name: clindamycin phosphate/dextrose 5 % in water 300 mg/50 mL INTRAVEN IV SOLUTION, PIGGYBACK, BOTTLE (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water 300 ml twice daily for 14 days
Study: 11263780
Drug: High-dose penicillamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose penicillamine
Study: 11083272
Drug: Low-dose penicillamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose penicillamine
Study: 6398982
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum (21 g per day, taken with meals three times a day)
Study: 25345628
Drug: Perampanel (PER)
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perampanel (PER) 4 mg/day
Study: 25345628
Drug: Perampanel (PER)
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perampanel (PER) 8 mg/day
Study: 25345628
Drug: Perampanel (PER)
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perampanel (PER) 12 mg/day
Study: 25345628
Drug: Perampanel (PER)
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perampanel (PER) long-term treatment (10 or 12 mg/day)
Study: 25345628
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events (AEs) with any dose of PER
Study: 16599033
Drug: Metoclopramide 0.1‐0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 0.1‐0.2 mg kg(‐1)
Study: 16599033
Drug: Prochlorperazine 0.1‐0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine 0.1‐0.2 mg kg(‐1)
Study: 9929022
Drug: L-NMMA (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (6 mg/kg intravenous infusion)
Study: 7478254
Drug: Tetrahydroaminoacridine (THA)
Normalized name: Tetrahydroaminoacridine
DrugBank: Tacrine (DB00382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetrahydroaminoacridine (THA) 75 mg
Study: 7478254
Drug: Tetrahydroaminoacridine (THA)
Normalized name: Tetrahydroaminoacridine
DrugBank: Tacrine (DB00382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetrahydroaminoacridine (THA) 25 mg
Study: 7478254
Drug: Tetrahydroaminoacridine (THA)
Normalized name: Tetrahydroaminoacridine
DrugBank: Tacrine (DB00382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetrahydroaminoacridine (THA) 25 or 75 mg
Study: 2123433
Drug: Cerebrolysin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin plus multi-vitamins infusions
Study: 28081673
Drug: lopinavir/ritonavir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir plus lamivudine (dual therapy)
Study: 28081673
Drug: lopinavir/ritonavir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir plus 2 NRTI (triple therapy)
Study: 15547020
Drug: Nicorandil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (20 mg twice daily)
Study: 9424198
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of phytoadaptogen (Adapt)
Study: 8221501
Drug: Meeting a
Normalized name: Dolce and Gabbana Meet Your Flawless Matte Skin Duo KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meeting a person with AIDS in the classroom (treatment group)
Study: 31580698
Drug: Resistive Tecar
Normalized name: Tecartus
DrugBank: Brexucabtagene autoleucel (DB15699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistive Tecar Therapy (TT)
Study: 31580698
Drug: Capacitive Tecar
Normalized name: Tecartus
DrugBank: Brexucabtagene autoleucel (DB15699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capacitive Tecar Therapy (TT)
Study: 18925430
Drug: Recombinant HCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant HCG (rHCG) - 250 microg subcutaneous injection
Study: 18925430
Drug: Urinary HCG
Normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary HCG (uHCG) - 10,000 IU intramuscular injection
Study: 15672335
Drug: 0.10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.10 mg/kg morphine IV bolus
Study: 8759532
Drug: Otovent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otovent treatment set
Study: 2012010
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg palmvitee capsules/day
Study: 2012010
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg gamma-tocotrienol/d
Study: 2012010
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg corn oil/d
Study: 7356903
Drug: Cimetidine treatment
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine treatment
Study: 29289383
Drug: HBsAg-1018 (HEPLISAV-B™)
Normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBsAg-1018 (HEPLISAV-B™) administered intramuscularly at weeks 0 and 4
Study: 29289383
Drug: HBsAg-Eng (Engerix-B®)
Normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBsAg-Eng (Engerix-B®) administered at weeks 0, 4, and 24
Study: 26968277
Drug: Conjugated linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated linoleic acid (5.6 g/day)
Study: 26968277
Drug: Oral paraffin
Normalized name: Paraffin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paraffin (placebo)
Study: 22228325
Drug: Tracheal/esophageal traction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tracheal/esophageal traction exercise (TTE) treatment for 3 consecutive days before surgery
Study: 22228325
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no TTE treatment)
Study: 19306024
Drug: Myrtle oral
Normalized name: myrtle leaf oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myrtle oral paste applied four times a day for 6 days
Study: 18366729
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Analysis System of Psychotherapy (CBASP) in combination with medication
Study: 18366729
Drug: Usual secondary
Normalized name: Secondary potassium phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual secondary care in combination with medication
Study: 16113617
Drug: TAU SSRI
Normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU SSRI plus brief cognitive-behavioral therapy (CBT) (n = 77)
Study: 16113617
Drug: Treatment-as-usual (TAU)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (TAU) control condition (n = 75)
Study: 12455393
Drug: Mycobacterium w
Normalized name: Mycobacterium W Vaccine
DrugBank: Mycobacterium w. Vaccine (DB15798)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycobacterium w plus two antiretroviral agents
Study: 2029855
Drug: Transcranial electric
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transcranial electric treatment (TET) with constant current and pulse current of square impulses of 70-80 Hz
Study: 7332089
Drug: Tramadol-HCl continuous
Normalized name: Tramadol Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol-HCl continuous infusion
Study: 30124459
Drug: Robot-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted therapy (30 min per session, 5 sessions per week for 8 weeks)
Study: 30124459
Drug: General occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: General occupational therapy (30 min per session, 5 sessions per week for 8 weeks)
Study: 26914592
Drug: CPAP usage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP usage for <4 hours per night or no treatment
Study: 9596431
Drug: Nebulized glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nebulized glucagon (2 mg)
Study: 3042994
Drug: Intravenous regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous regular insulin (0.0, 0.5, 1.0, 2.0, 3.0, and 4.0 units)
Study: 3042994
Drug: Intravenous regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous regular insulin (various doses)
Study: 26349115
Drug: Garenoxacin 200
Normalized name: Garénoxacine
DrugBank: Garenoxacin (DB06160)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Garenoxacin 200 mg
Study: 26349115
Drug: Garenoxacin 400
Normalized name: Garénoxacine
DrugBank: Garenoxacin (DB06160)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Garenoxacin 400 mg
Study: 23131836
Drug: Video-assisted swallowing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video-assisted swallowing therapy (VAST)
Study: 21905793
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no hemostatic agents)
Study: 8225637
Drug: Clarithromycin (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (125 mg for <25 kg or 250 mg for >25 kg, twice daily for 5 days)
Study: 8225637
Drug: Amoxycillin (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (125 mg for <25 kg or 250 mg for >25 kg, three times daily for 5 days)
Study: 12618501
Drug: Vinorelbine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine (30 mg/m²)
Study: 12618501
Drug: Gemcitabine (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1200 mg/m²)
Study: 12618501
Drug: Vinorelbine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine (25 mg/m²) plus Gemcitabine (1000 mg/m²)
Study: 12618501
Drug: Quality of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality of life across all treatment arms
Study: 8145392
Drug: Males spending
Normalized name: Malus domestica leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Males spending 7 hours or more outside daily
Study: 3021500
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 mg q.i.d.)
Study: 14631124
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with azathioprine (AZA) and interferon beta(1a)
Study: 9407252
Drug: Increased carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased carbohydrate intake (CHO) of 10 g.kg‐1 bm during the 22‐hr recovery
Study: 8498900
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant human erythropoietin (rh‐EPO) therapy
Study: 8498900
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no rh‐EPO therapy in the first year)
Study: 3079056
Drug: Antilymphoblast globulin
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antilymphoblast globulin (ALG) therapy
Study: 28752418
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (120 mg docosahexaenoic acid and 180 mg eicosapentaenoic acid) daily
Study: 24942756
Drug: Irradiated, granulocyte‐macrophage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiated, granulocyte‐macrophage colony‐stimulating factor (GM‐CSF)‐secreting, allogeneic PDAC vaccine (GVAX)
Study: 24942756
Drug: GVAX in
Normalized name: GVAX
DrugBank: GVAX (DB17276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GVAX in combination with low‐dose cyclophosphamide
Study: 22526159
Drug: Intravenous treosulfan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous treosulfan (7,000 mg/m2 on day 1 of a 28-day cycle)
Study: 22526159
Drug: Oral treosulfan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treosulfan (600 mg/m2 on days 1-28 of a 56-day cycle)
Study: 18374336
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pioglitazone and simvastatin
Study: 15991880
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate 800 mg following a standard high‐fat content meal
Study: 15991880
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate 800 mg following 10 hours of fasting
Study: 12495202
Drug: Sulfated polysaccharides
Normalized name: sulfated mucopolysaccharides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfated polysaccharides from red microalgae (topical application)
Study: 10384681
Drug: SF-36 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: SF-36 administered via in-person or telephone interviews
Study: 10384681
Drug: Self-administered SF-36
Normalized name: SF-RI 1
DrugBank: Calfactant (DB06415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered SF-36
Study: 8679062
Drug: Antidementia drug
Normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antidementia drug tacrine
Study: 7070885
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg albuterol syrup (2 mg/5 ml) four times a day
Study: 7070885
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg albuterol syrup
Study: 7070885
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg albuterol tablets
Study: 3511776
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg albuterol
Study: 30831103
Drug: Buccal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal misoprostol 800 mcg every 3 hours for three doses
Study: 30831103
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol 800 mcg every 3 hours for three doses
Study: 30831103
Drug: Buccal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal misoprostol with additional misoprostol at follow-up
Study: 30831103
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol with additional misoprostol at follow-up
Study: 17237451
Drug: Formats with
Normalized name: formate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formats with a number (e.g., pie charts, vertical bars, horizontal bars, digits, systematic ovals, random ovals)
Study: 17237451
Drug: Formats with
Normalized name: formate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formats with only a scale (e.g., pie charts, random ovals)
Study: 15281471
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate DPI, 400 microg every evening (1 puff daily)
Study: 15281471
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate MDI, two 125-microg puffs twice daily
Study: 12045412
Drug: Various medications
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various medications for treatment of status asthmaticus; specific drugs, doses, and duration not available.
Study: 12045412
Drug: Elimination of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elimination of cost-adding treatments without improved quality of care; specific interventions not available.
Study: 2172395
Drug: Intranasal beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal beclomethasone (168 micrograms twice a day) and oral prednisone (30 mg twice daily)
Study: 9467537
Drug: Midodrine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (10 mg)
Study: 24471250
Drug: Prasugrel (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (loading dose of 60 mg followed by maintenance dose of 10 mg once daily)
Study: 24471250
Drug: Clopidogrel (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (loading dose of 300 mg followed by maintenance dose of 75 mg once daily)
Study: 21212103
Drug: High-dose octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose octreotide LAR (60 mg/28 days)
Study: 21212103
Drug: High-frequency octreotide
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency octreotide LAR (30 mg/21 days)
Study: 21212103
Drug: High-dose octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose octreotide LAR
Study: 17302367
Drug: LB80380 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: LB80380 30 mg once per day
Study: 17302367
Drug: LB80380 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: LB80380 60 mg once per day